Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. ("Shangyao Xinya"), recently received the "Drug Supplement Approval Notice" (Notice No.: 2025B05069, 2025B05110, 2025B05111) from the National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection and Aztreonam for Injection, indicating that these drugs have passed the consistency evaluation for generic drugs in terms of quality and efficacy.

Cefuroxime Sodium for Injection is indicated for the treatment of infections caused by susceptible microorganisms, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections. Aztreonam for Injection is used to treat infections caused by susceptible Gram-negative bacteria, including urinary tract infections (complicated and uncomplicated), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.